Key Highlights
- Appointed as Chief Commercial Officer at Stoke Therapeutics, overseeing global strategy for STK-001.
- Brings over 20 years of biopharma experience, including roles at Provention Bio and Dova Pharmaceuticals.
- Aimed to advance STK-001 as the first disease-modifying treatment for Dravet syndrome.
Source: Business Wire
Notable Quotes
- “Jason brings deep expertise and a proven track record in successfully driving commercial strategies for novel new medicines,” – Edward M. Kaye, M.D., Chief Executive Officer at Stoke Therapeutics
- “I am excited by the opportunity to build on the strong foundation of scientific innovation and clinical execution as we prepare the company to successfully conduct a registrational study and commercialize STK-001,” – Jason Hoitt, Chief Commercial Officer at Stoke Therapeutics
SoHC's Take
The appointment of Jason Hoitt as Chief Commercial Officer is a strategic move for Stoke Therapeutics as it prepares for the pivotal trials and potential commercialization of STK-001, aimed at treating Dravet syndrome. Hoitt’s extensive experience in managing commercial strategies for innovative therapies, particularly in the rare disease sector, will be invaluable. His prior successes in leading commercial launches at Provention Bio and Dova Pharmaceuticals highlight his capability to potentially steer STK-001 to market success. This could mark a significant advancement in addressing the underlying causes of severe diseases, rather than just managing symptoms, potentially setting a new standard in the treatment landscape for Dravet syndrome.
